Related Experiment Video
Updated: Jun 19, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis
1University of Western Ontario, Department of Epidemiology and Biostatistics, London, Ontario, N6A 5C1, Canada. jeffhoch@biostats.uwo.ca
Abstract:
In this article, an overview of lessons from cost-effectiveness analyses of disease-modifying drugs for the treatment of multiple sclerosis is provided. Special attention is paid to the uncertainty in reaching a conclusion from the economic evaluations. If recent debates over multiple sclerosis drugs are any indication, the public's understanding of why one conducts an economic evaluation may be at least as important as the cost-effectiveness estimate from the analysis.
More Related Videos
Related Concept Videos
Multiple Sclerosis l: Introduction
Therapeutic Drug Monitoring: Affecting Factors
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

